Treatment of recurrent multiresistant Escherichia coli prostatitis with azithromycin

Jiang, Simon H T; Collignon, Peter J

doi:10.5694/j.1326-5377.2011.tb03780.x

Topics

To the Editor: Resistant gram-negative bacteria (especially Escherichia coli) are a major and growing problem worldwide.1 Some strains are resistant to all available antibiotics.2

The Canberra Hospital, Canberra, ACT.

Correspondence: peter.collignon@act.gov.au

1. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
2. Fernando GA, Collignon PJ, Bell JM. A risk for returned travellers: the “post-antibiotic era”. Med J Aust 2010; 193: 59. <eMJA full text> <MJA full text>
3. Parry CM, Ho VA, Phuong le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin–azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007; 51: 819-825.
4. Skerk V, Krhen I, Lisi M, et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004; 24: 188-191.
5. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1993; 37: 1203-1205.

Online responses are no longer available. Please refer to our instructions for authors page for more information.